Philips launches iPill for localized drug delivery

Philips Research has released the iPill, its next generation camera pill, which can be electronically programmed to control the delivery of medicine according to a pre-defined drug release profile.

The iPill determines its location in the intestinal tract by measuring the local acidity or pH of its environment. Armed with this pH information and data about capsule transit times, the location in the gut can be determined with good accuracy. The iPill releases medicine from its drug reservoir via a microprocessor controlled pump, allowing programmable drug delivery. In addition, the capsule is designed to measure local temperature and report measurements wirelessly to an external receiver unit, according to the company.

Locations where the drug needs to be released could also be determined by medical imaging – for example, endoscopy, MRI or CT scans, Philips said.

In the form of an 11- x 26-mm capsule, the iPill incorporates a microprocessor, battery, pH sensor, temperature sensor, RF wireless transceiver, fluid pump and drug reservoir. It communicates via its wireless transceiver to a control unit outside the body, the company said.

Around the web

The new technology shows early potential to make a significant impact on imaging workflows and patient care. 

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.
 

The two companies aim to improve patient access to high-quality MRI scans by combining their artificial intelligence capabilities.